Critical Role of Flavin and Glutathione in Complex I–Mediated Bioenergetic Failure in Brain Ischemia/Reperfusion Injury

Anja Kahl, MD*; Anna Stepanova, MS*; Csaba Konrad, PhD; Corey Anderson, BS; Giovanni Manfredi, MD, PhD; Ping Zhou, PhD; Costantino Iadecola, MD; Alexander Galkin, PhD

Background and Purpose—Ischemic brain injury is characterized by 2 temporally distinct but interrelated phases: ischemia (primary energy failure) and reperfusion (secondary energy failure). Loss of cerebral blood flow leads to decreased oxygen levels and energy crisis in the ischemic area, initiating a sequence of pathophysiological events that after reoxygenation lead to ischemia/reperfusion (I/R) brain damage. Mitochondrial impairment and oxidative stress are known to be early events in I/R injury. However, the biochemical mechanisms of mitochondria damage in I/R are not completely understood.

Methods—We used a mouse model of transient focal cerebral ischemia to investigate acute I/R-induced changes of mitochondrial function, focusing on mechanisms of primary and secondary energy failure.

Results—Ischemia induced a reversible loss of flavin mononucleotide from mitochondrial complex I leading to a transient decrease in its enzymatic activity, which is rapidly reversed on reoxygenation. Reestablishing blood flow led to a reversible oxidative modification of mitochondrial complex I thiol residues and inhibition of the enzyme. Administration of glutathione-ethyl ester at the onset of reperfusion prevented the decline of complex I activity and was associated with smaller infarct size and improved neurological outcome, suggesting that decreased oxidation of complex I thios during I/R-induced oxidative stress may contribute to the neuroprotective effect of glutathione ester.

Conclusions—Our results unveil a key role of mitochondrial complex I in the development of I/R brain injury and provide the mechanistic basis for the well-established mitochondrial dysfunction caused by I/R. Targeting the functional integrity of complex I in the early phase of reperfusion may provide a novel therapeutic strategy to prevent tissue injury after stroke.

Visual Overview—An online visual overview is available for this article. (Stroke. 2018;49:00-00. DOI: 10.1161/STROKEAHA.117.019687.)

Key Words: flavin mononucleotide ■ glutathione ■ mitochondria ■ oxidative stress ■ reperfusion
failure or changes in substrate availability as the cause of the secondary energy depletion and cell death.\textsuperscript{11,12} In fact, data indicate that secondary energy failure after transient ischemia might be the result of delayed mitochondrial damage, likely because of oxidative stress.\textsuperscript{11,12} Mitochondrial electron transport chain (ETC) enzymes are known to become rapidly over-reduced in the absence of oxygen and to be damaged by subsequent reoxygenation.\textsuperscript{11,13,14} However, despite intensive research, the molecular mechanisms of mitochondria damage in I/R remain to be elucidated.

Here, we used a mouse model of middle cerebral artery occlusion (MCAO) to investigate acute I/R-induced changes of mitochondrial function, focusing on the molecular and biochemical mechanisms of primary and secondary energy failure. Our results suggest a central role of mitochondrial complex I (C-I) impairment in the development of bioenergetic failure after acute I/R brain injury. Protection of C-I enzymatic function during ischemia and the initial stages of reperfusion could be an effective approach to prevent subsequent detrimental events in the I/R cascade, ultimately preserving neuronal integrity and reducing brain damage after stroke.

Materials and Methods

All data and materials have been made publicly available at the https://pure.qub.ac.uk/portal/ repository, and a detailed Methods section is available in the online-only Data Supplement.

MCAO Model

All procedures were approved by the Institutional Animal Care and Use Committee of Well Cornell Medicine and performed in accordance with the ARRIVE guidelines (Animals in Research: Reporting In Vivo Experiment).\textsuperscript{11} Transient MCAO was induced using an intraluminal filament as described.\textsuperscript{16} In brief, 7 to 9-week-old male mice were anesthetized with 1.5% to 2.0% isoflurane and rectal temperature was maintained at 37\+\textdegree\textpm\textdegree\textperiodcentered C. Cerebral blood flow was measured with laser-Doppler flowmetry (Periflux System 5010; Perimed) in the ischemic center (2 mm posterior, 5 mm lateral to bregma). After 35 minutes, the filament was retracted and cerebral blood flow reestablished. This duration of cerebral ischemia has been used extensively by us\textsuperscript{16,17} and others\textsuperscript{18,19} and leads to reproducible infarct volumes of 50 to 60 mm\textsuperscript{3} and measurable neurological deficits. Only animals that exhibited a reduction in cerebral blood flow 85% during MCAO and in which cerebral blood flow recovered by 80% after 10 minutes of reperfusion were included in the study.\textsuperscript{20,21} Three days after, MCAO functional impairment was assessed and infarct volume was quantified in cresyl violet–stained sections and corrected for swelling, as previously described.\textsuperscript{16}

Administration of Glutathione-Ester and Glutathione Content Measurement

Reduced glutathione-ethyl ester (G1404; Sigma Aldrich) was administered immediately after the initiation of reperfusion via jugular vein (400 mg/kg). Saline injections served as control. Total glutathione content was determined using Glutathione Assay Kit (703002; Cayman).

Mitochondrial Measurements

After MCAO alone or MCAO with a period of recirculation as indicated, mice were decapitated. Brains were removed and a standardized 4 mm MCA area tissue sample dissected using a mouse brain matrix (Zivic Instruments). The brain sample was homogenized in ice-cold isolation buffer (in mmol/L: 210 mannitol, 70 sucrose, 1 ethylene glycol-bis(β-aminoethyl ether)-N,N',N'-tetraacetic acid, 5 HEPES, pH 7.4) with 80 strokes of a Dounce homogenizer. The homogenate was centrifuged at 1000g for 5 minutes at 4\degree C and the supernatant was collected and used for respiration analysis. Respiration was measured using Oxygraph-2k (Oroboros Instruments).

For isolation of mitochondria, brain homogenates were centrifuged for 15 minutes at 20000g. The obtained membrane pellet was rinsed twice with (in mmol/L): 250 sucrose, 50 Tris-HCl (pH 7.5), 0.2 EDTA medium, and subsequently resuspended in the same medium. Frozen aliquots were stored at \textdegree 80\degree C until use. Protein content was determined by bicinchoninic acid assay (Sigma) with 0.1% deoxycholate for solubilization of mitochondrial membranes.

Mitochondria and Respiratory Chain Analysis

Activities of respiratory chain enzyme and citrate synthase were measured spectrophotometrically as described.\textsuperscript{22} Flavin mononucleotide (FMN) was determined fluorometrically.\textsuperscript{22} Immunoblot analyses were performed using OXPHOS antibody cocktail (ab110413; Abcam).\textsuperscript{22}

Experimental Design and Statistical Analysis

Mice were randomly assigned to the experimental groups, and analyses were performed by an investigator blinded to the treatment protocol. Data are expressed as mean±SEM. Differences were considered statistically significant when \(P<0.05\). Details of statistical analyses are indicated in the Figure legends and online-only Data Supplement.

Results

Multiphasic Impairment of Mitochondrial Respiration in I/R

We studied I/R-induced changes of mitochondrial function in a mouse model of focal ischemia after transient MCAO. Figure 1A shows representative traces of malate/glutamate-supported respiration of brain homogenates of sham and after 35 minutes ischemia. ADP-stimulated mitochondrial respiration showed multiphasic impairment after I/R (Figure 1B). A decline (59.0±5.9% of sham control; \(P<0.05\); n=4 per group) was observed during ischemia, followed by a partial recovery (79.6±5.4% of control; \(P>0.05\); n=5 per group) at 10 minutes of reperfusion, and by a subsequent profound decline in respiration (50.7±6.2% of control; \(P<0.05\); n=5 per group) at 30 minutes of reperfusion. These early changes in mitochondrial function were followed by a recovery of respiration at 1 hour of reperfusion (84.7±2.3% of control; \(P>0.05\); n=5 per group) and then by a progressive decline in respiration, occurring 2 to 24 hours (55±7.8% of control; \(P<0.05\); n=5 per group, at 24 hours) after reperfusion (Figure 1B).

Citrate synthase activity, an indicator of mitochondrial content, did not significantly differ from control at any time point (\(P>0.05\); n=3–7 per group; Figure 1C). Further, we did not detect significant changes in the protein levels of ETC complexes I to V and mitochondrial respiratory control ratio, during the ischemic phase or within 24 hours after reperfusion (Figure I in the online-only Data Supplement).

Activities of Individual Mitochondrial Membrane Complexes Are Differently Affected in I/R

We note that brain homogenates included nonsynaptic mitochondria but also synaptosomes containing synaptic mitochondria. The synaptic mitochondria, however, do not contribute
Kahl et al
Mitochondrial Complex I Impairment in Stroke

3

to ADP-stimulated respiration, because of restricted ADP access to synaptosomes. Respiration measured in whole tissue homogenates is a product of several processes including transport of substrates, activities of NAD-dependent dehydrogenases, and ETC.

For ETC activity measurements, substrate delivery into all mitochondrial populations was ensured by addition of the membrane-permeabilizing agent alamethicin. To specifically assay for I/R-induced changes in ETC complexes, we assessed the overall activity of the respiratory chain by measuring NADH oxidase (complexes I+III+IV; Figure 1D). The temporal profile of NADH oxidase activity changes strongly corresponded to the multiphasic pattern observed for the mitochondrial respiration (Figure 1B), suggesting that the observed mitochondrial dysfunction is a result of I/R-induced ETC impairment.

Next, we measured the activities of individual ETC complexes: succinate dehydrogenase (C-II), ferrocytochrome c oxidase (C-IV), and NADH:ubiquinone oxidoreductase (C-I), as well as succinate:cytochrome c reductase (C-II+C-III). C-II–linked activities were not affected at any time point after I/R, indicating that C-II and C-III were not responsible for the I/R-induced mitochondrial dysfunction (P>0.05; n=4–7 per group; Figure 2A; C-II+III data not shown).

C-IV activity was lower at all time points compared with sham (63.7±9.1% at 24 hours; P<0.05; n=4; Figure 2B). However, the decline of C-IV did not follow the multiphasic pattern observed in ADP-stimulated respiration and NADH oxidase activity, suggesting that the mechanism of C-IV and NADH oxidase impairment is different and that C-IV is not responsible for the I/R-induced changes.

Complex I Impairment Is Associated With the Multiphasic Pattern of Respiratory Decline in I/R

To elucidate the mechanisms of C-I impairment, we measured the physiological activity and the relative amount of C-I using two different approaches. The physiological activity of C-I was assessed as NADH:Q1 reductase. The relative content of C-I (proportional to flavin [FMN] content in the enzyme) was determined as oxidation of NADH by hexaammineruthenium (HAR). The NADH:HAR reaction occurs only at the head of the enzyme, where HAR accepts electrons from the FMN, the first redox center of C-I.24

The physiological activity of C-I (Figure 2C) followed the same pattern as ADP-stimulated respiration (Figure 1B) and NADH oxidase activity (Figure 1D), indicating that the impairment of oxidative phosphorylation in the
ischemic tissue was because of a specific dysfunction of C-I. Interestingly, NADH:HAR reductase showed an apparent decrease in the relative content of C-I after 35 minutes of ischemia (68.7±1.3%; \( P = 0.0001; n=6 \) per group), followed by a rapid recovery after reoxygenation (97.0±3.9%; \( P = 0.99; n=6 \) per group) and a slow gradual decline at subsequent time points after I/R injury (78.7±4.3%; \( P = 0.0003; n=8 \) per group; Figure 2D).

Figure 2. Enzymatic activities of respiratory chain complexes are differently affected after ischemia/reperfusion (I/R). A, Complex II (C-II), B, C-IV, and C, C-I NADH:Q1 and D, C-I NADH:hexaammineruthenium (HAR) reductase activities were measured in whole tissue homogenates; \( n=4 \) to 12 per group; Kruskal–Wallis test.

Figure 3. Complex I (C-I) impairment is associated with the multiphasic pattern of respiratory decline observed in ischemia/reperfusion (I/R). A, Overall activity of C-I at critical time points after I/R in mitochondrial membranes. B, In vitro time course of the reductive inactivation of NADH:hexaammineruthenium (HAR) reductase activity in mitochondrial membranes. Ischemic over-reduction of the ETC resulted in a decrease of the relative amount of C-I (red line) compared with control (black line). Addition of reduced FMN restored NADH:HAR reductase activity (arrow). C, Decrease of FMN in mitochondrial membranes obtained from the ischemic area after 35 minutes of middle cerebral artery occlusion (MCAO) compared with sham controls (\( n=6–12 \) per group; \( P = 0.0048; \) ANOVA). n.s. indicates not significant.
On the basis of the results above, we identified 35 minutes ischemia and 30 minutes, 1 hour, and 24 hours of reperfusion as critical time points for the development of mitochondrial dysfunction in I/R injury. To further elucidate the mechanism of C-I impairment, we assayed NADH:Q₁ reductase activity in preparations of mitochondrial membranes isolated at these time points.

As shown in Figure 3A, 35 minutes ischemia resulted in a robust decline of NADH:Q₁ reductase and NADH:Q₂ activity (74.2±4.2% and 80.5±2.7%, n=5 per group, respectively). A significant decrease in NADH:Q₂ activity at 30 minutes (71.2±2.3%; n=4 per group), recovery at 1 hour (92.7±2.1%; n=6 per group), and another activity decline at 24 hours (58.9±3.3%; n=4 per group) of reperfusion was observed, confirming the results in whole tissue homogenates.

Conversely, NADH:Q₄ activity showed a transient recovery at 30 minutes and 1 hour (92.9±2.9%; n=4 per group; 90.9±3.5%; n=6 per group, respectively) followed by a gradual decline at 24 hours after reoxygenation (77.2±2.0%; n=4 per group; Figure 3A).

The drop in physiological NADH:Q₂ reductase activity could be explained by two fundamentally different mechanisms: a decline in C-I content or a decrease in the catalytic efficiency of C-I (number of NADH molecules oxidized by 1 enzyme molecule per minute). To estimate the relative catalytic efficiency of C-I, the ratio of NADH:Q₁/NADH:Q₄ reductase (Q₁/HAR) was calculated as previously described.²⁵ No significant reduction in the catalytic efficiency of C-I after 35 minutes of ischemia (92.1±4.2%; P<0.05; n=5 per group) was observed. After reperfusion, a substantial decline in the efficiency of the enzyme was found at 30 minutes (76.8±2.8%; P<0.05; n=4 per group), followed by a complete recovery at 1 hour (102.6±4.0%; P>0.05; n=6 per group), and another decline at 24 hours (79.4±6.0%; P>0.05; n=4 per group) after I/R (Figure 3A). Note that although there was a significant decrease in NADH:Q₁ and NADH:Q₄ reductase activities at 35 minutes ischemia, the Q₁/HAR ratio did not change. This could be interpreted as decrease in the number of functional C-I molecules in the membrane with no change in the individual C-I enzyme catalytic efficiency (Q₁/HAR).

**Functional Impairment C-I in Ischemia Is Because of a Loss of FMN**

To further explore the transient decrease of NADH:Q₄ reductase after 35 minutes of ischemia, we performed in vitro experiments. Brain mitochondrial membranes from naive animals were incubated in conditions of metabolic reductive hypoxia,²⁶ mimicking the over-reduction of the ETC in ischemia (Figure 3B). The first redox center of C-I, noncovalently bound FMN, is capable of dissociating from the enzyme.²⁷ We found that incubation of mitochondrial membranes in reductive conditions resulted in a rapid decline of the HAR reductase activity over time, which seemed as a decrease of C-I content.

To confirm these in vitro findings, we determined the content of noncovalently bound FMN in mitochondrial membranes isolated at the critical time points after I/R. We found a significant decline of FMN content in the samples obtained after 35 minutes of ischemia (Figure 3C). This drop correlated with the decrease in NADH:Q₁ reductase activity in the same samples (Figure 3A, red bar) indicating ischemia-induced loss of FMN from the enzyme without a decrease in C-I content.

**Glutathione Improves C-I Dysfunction and Neurological Outcome After I/R**

Reperfusion-induced oxidative stress is one of the main contributors to tissue injury in I/R.²⁸,²⁹ Intracellular glutathione-dependent enzymatic systems regulate the thiol-based redox homeostasis and play a major role in the protection against oxidative stress. As shown in Figure 4A, I/R resulted in a significant decline of total glutathione content in the affected area in comparison to the contralateral hemisphere or sham. To test if reduced glutathione is able to confer a C-I–linked neuroprotection in vivo, we administered membrane-permeable glutathione-ethyl ester at the onset of reperfusion. Glutathione-ethyl ester restored total glutathione content in the ipsilateral hemisphere to control values (Figure 4A), indicating that it is able to penetrate into the brain tissue and interact with cellular glutathione pool. Furthermore, administration
of glutathione-ethyl ester led to a 61% reduction in infarct volume (glutathione: 25.9±4.4 mm³ versus control: 66.8±7.0 mm³; P=0.0002; n=8–9 per group; Figure 4B and 4C), which correlated with decreased body weight loss (glutathione: 7.0±2.4% versus control: 19.8±2.9%; P=0.0037; n=8–9 per group; Figure IIA in the online-only Data Supplement). Overall functional outcome, assessed by the hanging wire test (Figure 4D) and modified Bederson score (Figure IIB in the online-only Data Supplement), was also improved compared with saline-treated controls.

Glutathione Prevents Mitochondrial Dysfunction and C-I Activity Decline Early After I/R

To test the effect of glutathione-ethyl ester administration on mitochondrial function in vivo, we measured mitochondrial respiration 30 minutes after the onset of reperfusion comparing glutathione-treated mice and saline-treated controls. A significant increase in respiration was observed in tissue homogenates prepared from the ischemic area of glutathione-treated mice compared with saline-treated animals subjected to MCAO (P=0.03; n=5–6 per group; Figure 5A). These findings were associated with an increase in NADH:Q₁ activity (P=0.0002; n=6 per group; Figure 5B). NADH:HAR activity was not affected (P>0.05; n=6 per group; Figure 5C) at 30 minutes of reperfusion.

Mitochondrial membranes isolated from the ischemic area of untreated animals at the critical time points after MCAO were preincubated ex vivo with thiol-reducing agent glutathione. NADH:Q₁ and NADH:HAR activity were measured before and after glutathione incubation (Figure 5D). Pre-incubation with glutathione was able to recover NADH:Q₁ activity in membranes obtained at 30 minutes of reperfusion (Figure 5D), indicating that reversible oxidation of C-I thiols is the underlying post-translational modification early after reperfusion. In contrast, glutathione treatment did not affect NADH:Q₁ activity at 24 hours of reperfusion, pointing to an irreversible decline of C-I catalytic efficiency at later time points.

**Discussion**

In the present study, we established a spatiotemporal profile of biochemical mechanisms contributing to the evolution of mitochondrial bioenergetic failure in I/R using a mouse model of transient MCAO. Using brain homogenates, we demonstrate an I/R-induced, multiphasic pattern of mitochondrial respiratory dysfunction in the brain, which to our knowledge has not been described before (Figure 6). We observed an initial decline in respiration after 35 minutes of ischemia, which is in agreement with previously published studies.²⁸,³⁰ The rapid partial recovery of mitochondrial respiration after 10 minutes of reperfusion followed by a first reflow-induced respiratory decline at 30 minutes of reoxygenation has never been reported. This decline in tissue respiration was followed by an almost full recovery at 1 hour with a slow decrease at later reperfusion time points (4–24 hours). In the samples from all time points, citrate synthase activity was similar to the sham controls, indicating preservation of mitochondrial mass, for 24 hours post-ischemia.

The rate of mitochondrial respiration can be used as a predictor of tissue survival after I/R.³¹ Our tissue preparations

---

**Figure 5.** Glutathione (GSH) ester treatment improves complex I (C-I)–mediated bioenergetic failure early after reperfusion. A, GSH ester treatment ameliorates mitochondrial respiratory decline at 30 minutes of reperfusion (n=5–6 per group; P=0.03; Mann–Whitney U test). B, C-I activity is significantly improved in GSH-treated mice compared with controls (n=5–6 per group; P<0.05; Mann–Whitney U test). C, No change in the relative amount of C-I was observed. D, In vitro pre-incubation of whole tissue homogenates with GSH was able to partially recover ischemia/reperfusion (I/R)-induced C-I activity decline 30 minutes after reperfusion (n=4 per group; P=0.0008; t tests). GSH treatment did not affect C-I activity in sham, 1 or 24 hours after reperfusion. MCAO indicates middle cerebral artery occlusion.
from the MCA area include a mixture of different brain cells so the observed changes in mitochondrial respiration cannot be exclusively attributed to only one cell type. Several publications have described a glia/neuron ratio of 0.4 to 0.35 in mouse brain, suggesting that neuronal mitochondria may contribute the major fraction of respiratory activity in brain homogenates.

We identified C-I as the key respiratory enzyme responsible for the multiphasic pattern of mitochondrial dysfunction in I/R. C-I has a high degree of flux control over oxidative phosphorylation and is considered to be the rate-limiting component of NADH oxidase activity within the ETC. Supporting our results, a comparable pattern of rotenone-sensitive C-I activity decline within 4 hours after reperfusion has been reported previously.

The observed progressive decline in the enzymatic activity of C-IV after I/R injury is likely because of a different mechanism. C-II and C-III were not significantly affected in I/R, which is in agreement with previous in vivo studies investigating mitochondrial membrane complexes in stroke.

Inhibition of NADH-dependent respiration after ischemia has been observed in many stroke studies, but the mechanism was never established. Our results strongly suggest that ischemia induces a reversible release of FMN from C-I that caused the robust decrease of enzyme activity, which was rapidly restored within 10 minutes of reflow. C-I contains 1 molecule of noncovalently bound FMN per molecule of the enzyme, and it is the main source of membrane-associated flavin in mitochondria. FMN release is likely to occur in ischemia because of complex I over-reduction via reverse electron transfer. Reductive dissociation of C-I FMN has been reported in vitro but has not been shown in physiological settings. The release of a significant amount of reduced FMN (30–40 µmol/L) to the mitochondrial matrix is potentially harmful for the cell. On reperfusion, reduced FMN can be quickly reoxidized by oxygen, generating an equimolar amount of H2O2 in the matrix and significantly contributing to I/R-induced oxidative stress and tissue injury.

Mitochondrial function depends strongly on the maintenance of a cellular redox balance. Reperfusion triggers a burst of reactive oxygen species formation directly damaging cells via several different mechanisms. A critical component in the mitochondrial antioxidant defense system is endogenous glutathione. Reduced glutathione prevents or repairs oxidative damage generated by reactive oxygen species. Glutathione homeostasis is severely affected after I/R, therefore, making protein thiols a major target of oxidative damage. Mitochondrial respiratory enzymes are particularly susceptible to reactive oxygen species-mediated modulation of the thiol redox systems.

We demonstrate that restoring total glutathione levels in the ischemic area at the onset of reperfusion is associated with...
protection of mitochondrial C-I activity and a robust neuroprotective effect. This is in agreement with previous studies showing a cytoprotective action of membrane-permeable thiol antioxidants against I/R-induced brain injury,\textsuperscript{46-48} but the mechanisms were not completely understood. Here, we presented evidence suggesting a reversible oxidation of critical thiols of C-I early after reperfusion, which is associated with a significant decrease in the enzymatic activity. Reconstitution of glutathione levels in vivo prevents mitochondrial bioenergetic dysfunction and C-I activity decline at 30 minutes of reperfusion. It should be noted that, in addition to protecting mitochondrial C-I, the antioxidant action of glutathione could also have beneficial impact through other cellular pathways, including inhibition of apoptosis\textsuperscript{48} and prevention of cytokine release.\textsuperscript{48} The ex vivo treatment of post-I/R mitochondrial membranes with glutathione recovered C-I activity at early, but not at late time points after reperfusion. Our data suggest that early reversible post-translational modifications of C-I are followed by an irreversible enzyme damage. On the basis of the neuroprotection of glutathione-ethyl ester and its positive effect on mitochondrial bioenergetics at 30 minutes of reperfusion, it is fair to speculate that this time point is particularly critical for the evolution of tissue infarction in our I/R model.

Conclusions

We provide the first evidence that focal cerebral ischemia induces a C-I-mediated pattern of mitochondrial respiratory decline early after I/R. The ischemia-induced impairment of C-I activity is because of the reversible dissociation of reduced flavin from the enzyme (Figure 6). Because FMNH, is a strong reactive oxygen species generator, this might be an important mechanism for the development of transient oxidative stress after reintroduction of oxygen on reperfusion.

Administration of ethyl ester of glutathione at the onset of reperfusion reduces infarction volume by 61% and improves neurological outcomes. This neuroprotective effect is associated with an increase of mitochondrial respiration and C-I activity. Thus, we conclude that reperfusion-induced C-I decline at 30 minutes after reperfusion is the result of a reversible modification of critical thiols of the enzyme. These findings indicate that preventing oxidative thiol modification of ETC early after the onset of reperfusion may be a viable approach to ameliorate mitochondrial dysfunction after I/R injury, ultimately reducing brain damage after stroke.

Sources of Funding

This study was supported by Medical Research Council UK grant MR/J007339/1 (Dr Galkin) and National Institutes of Health grants R01NS34179 (Dr Iadecola) and R01NS095692 (Dr Manfredi and Iadecola). Dr Kahl was recipient of a postdoctoral research grant from the Deutsche Forschungsgemeinschaft (KA3810/1-1).

Disclosures

None.

References

1. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation. 2016;133:e38–e360.
2. Campbell BC, Meretoja A, Donnan GA, Davis SM. Twenty-year history of the evolution of stroke thrombolysis with intravenous alteplase to reduce long-term disability. Stroke. 2015;46:2341–2346. doi: 10.1161/STROKEAHA.114.007564.
3. Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, et al; ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317–1329. doi: 10.1056/NEJMoa0804565.
4. Moskovitz MA, Lo EH, Iadecola C. The science of stroke: mechanisms in search of treatments. Neuron. 2010;67:181–198. doi: 10.1016/j.neuron.2010.07.002.
5. Sims NR, Muyderman H. Mitochondria, oxidative metabolism and cell death in stroke. Biochim Biophys Acta. 2010;1802:80–91. doi: 10.1016/j.bbadis.2009.09.003.
6. Diener GA, Hertz L. Astrocitogenic contributions to bioenergetics of cerebral ischemia. Glia. 2005;50:362–388. doi: 10.1002/glia.20157.
7. Hillered L, Siesjö BK, Aarfs KE. Mitochondrial response to transient forebrain ischemia and recirculation in the rat. J Cereb Blood Flow Metab. 1984;4:438–446. doi: 10.1038/jcbfm.1984.63.
8. Kristián T. Metabolic stages, mitochondria and calcium in hypoxic/ischemic brain damage. Cell Calcium. 2004;36:221–233. doi: 10.1016/j.ceca.2004.02.016.
9. Folbergrová J, Zhao Q, Katsura S, Siesjö BK. N-tert-buty1-alpha- phenylthioarsonate improves recovery of brain energy state in rats following transient focal ischemia. Proc Natl Acad Sci USA. 1995;92:5057–5061.
10. Lust WD, Taylor C, Pundlik S, Selman WR, Ratcheson RA. Ischemic cell death: dynamics of delayed secondary energy failure during reperfusion following focal ischemia. Metab Brain Dis. 2002;17:113–121.
11. Kuroda S, Katsura K, Hillered L, Bates TE, Siesjö BK. Delayed treatment with alpha-phenyl-N-tert-buty1 nitrone (PBN) attenuates secondary mitochondrial dysfunction after transient focal cerebral ischemia in the rat. Neurobiol Dis. 1996;3:149–157.
12. Siesjö BK, Elmére J, Janelidze S, Keep M, Kristián T, Ouyang YB, et al. Role and mechanisms of secondary mitochondrial failure. Acta Neurochir Suppl. 1999;73:7–13.
13. Sims NR, Pulssinelli WA. Altered mitochondrial respiration in selectively vulnerable brain subregions following transient forebrain ischemia in the rat. J Neurochem. 1987;49:1367–1374.
14. Niatsetskaya ZV, Charlangova P, Matsukievitch DA, Susonov SA, Mayurasakorn K, Ratner VI, et al. Mild hypoxemia during initial reperfusion alleviates the severity of secondary energy failure and protects brain in neonatal mice with hypoxic-ischemic injury. J Cereb Blood Flow Metab. 2012;32:232–241. doi: 10.1038/jcbfm.2011.164.
15. Kilkenny C, Brown WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol. 2010;8:e1000412. doi: 10.1371/journal.pbio.1000412.
16. Weickmann K, Kunz A, Iadecola C. Modelling focal cerebral ischemia in vivo. Methods Mol Biol. 2011;793:195–209. doi: 10.1007/978-1-61779-328-8_13.
17. Benakis C, Garcia-Bonilla L, Iadecola C, Anrather J. The role of microglia and myeloid immune cells in acute cerebral ischemia. Front Cell Neurosci. 2014;8:461. doi: 10.3389/fncel.2014.00461.
18. Garcia-Bonilla L, Benakis C, Moore J, Iadecola C, Anrather J. Immune mechanisms in cerebral ischemic tolerance. Front Cell Neurosci. 2014;8:44. doi: 10.3389/fncel.2014.00044.
19. Kim E, Tolhurst AT, Qin LY, Chen XY, Febbraio M, Cho S. CD36 fatty acid translocase, an inflammatory mediator, is involved in hyperlipidemia-induced exacerbation in ischemic brain injury. J Neurosci. 2008;28:4661–4670. doi: 10.1523/JNEUROSCI.0982-08.2008.
20. Park EM, Cho S, Fry S, Racchumi G, Zhou P, Anrather J, et al. Interaction between inducible nitric oxide synthase and poly(ADP-ribose) polymerase in focal ischemic brain injury. Stroke. 2004;35:2896–2901. doi: 10.1161/01.STR.0000147042.53659.6c.
21. Cho S, Park EM, Febbraio M, Anrather J, Park L, Racchumi G, et al. The class B scavenger receptor CD36 mediates free radical production and tissue injury in cerebral ischemia. J Neurosci. 2005;25:2504–2512. doi: 10.1523/JNEUROSCI.0035-05.2005.
22. Stepanova N, Shurbor Y, Valsecchi F, Manfredi G, Zalkin A. Differential susceptibility of mitochondrial complex II to inhibition by oxaloacetate in brain and heart. Biochim Biophys Acta. 2016;1857:1561–1568. doi: 10.1016/j.bbadis.2016.06.002.
23. Faeder RJ, Siegel LM. A rapid micromethod for determination of FMN and FAD in mixtures. Anal Biochem. 1973;53:332–336.
24. Sled VD, Vinogradov AD. Kinetics of the mitochondrial NADH-ubiquinone oxidoreductase interaction with hexammineruthenium(III). Biochim Biophys Acta. 1993;1141:262–268.
25. Gorenkova N, Robinson E, Grieve DJ, Galkin A. Conformational change of mitochondrial complex I increases ROS sensitivity during ischemia. *Antioxid Redox Signal*. 2013;19:1459–1468. doi: 10.1089/ars.2012.4698.

26. Moncada S, Erusalimsy JD. Does nitric oxide modulate mitochondrial energy generation and apoptosis? *Nat Rev Mol Cell Biol*. 2002;3:214–220. doi: 10.1038/nrm762.

27. Gostimskaya IS, Grivennikova VG, Cecchini G, Vinogradov AD. Reversible dissociation of flavin mononucleotide from the mammalian membrane-bound NADH:ubiquinone oxidoreductase (complex I). *FEBS Lett*. 2007;581:5803–5806. doi: 10.1016/j.febslet.2007.11.048.

28. Almeida A, Allen KL, Bates TE, Clark JB. Effect of reperfusion following cerebral ischaemia on the activity of the mitochondrial respiratory chain in the gerbil brain. *J Neurochem*. 1995;65:1698–1703.

29. Piantadosi CA, Zhang J. Mitochondrial generation of reactive oxygen species after brain ischemia. *Brain Res*. 1996;72:327–331; discussion 332.

30. Kliciues P, Hossmann KA, Pegg AE, Kobayashi K, Zimmermann V. Resuscitation of the monkey brain after one hour complete ischemia. III. Indications of metabolic recovery. *Brain Res*. 1975;5:61–73.

31. Hertz L. Bioenergetics of cerebral ischemia: a cellular perspective. *Neuropharmacology*. 2008;55:289–309. doi: 10.1016/j.neuropharm.2008.05.023.

32. Herculano-Houzel S, Watson C, Paxinos G. Distribution of neuronal cell bodies in the mouse cerebral cortex reveals quantitatively different cortical zones. *Front Neuroanat*. 2013;7:35. doi: 10.3389/fnana.2013.00035.

33. 2015;396:465–482. doi: 10.1038/nature09066.

34. Lienhart WD, Gudipati V, Machereux P. The human flavoproteome. *Arch Biochem Biophys*. 2013;535:150–162. doi: 10.1016/j.abb.2013.02.015.

35. Stupanova A, Kahl A, Konrad C, Ten V, Starkov AS, Galkin A. Reverse electron transfer results in a loss of flavin from mitochondrial complex I: potential mechanism for brain ischemia reperfusion injury. *J Cereb Blood Flow Metab*. 2017;37:3649–3658. doi: 10.1177/0271678X17730242.

36. Massey V. Activation of molecular oxygen by flavins and flavoproteins. *J Biol Chem*. 1994;269:22459–22462.

37. Kalogeris T, Bao Y, Korthuis RJ. Mitochondrial reactive oxygen species: a double edged sword in ischemia/reperfusion vs preconditioning. *Redox Biol*. 2014;2:702–714. doi: 10.1016/j.redox.2014.05.006.

38. Mizui T, Kinouchi H, Chan PH. Depletion of brain glutathione by buthionine sulfoximine enhances cerebral ischemic injury in rats. *Am J Physiol Heart Circ Physiol*. 1997;262(2 pt 2):H313–H317. doi: 10.1152/ajpheart.1997.262.2.H313.

39. Zaidan E, Sims NR. Alterations in the glutathione content of mitochondria following short-term forebrain ischemia in rats. *Neurosci Lett*. 1996;218:75–78.

40. Anderson MF, Sims NR. The effects of focal ischemia and reperfusion on the glutathione content of mitochondria from rat brain subregions. *J Neurochem*. 2002;81:541–549.

41. Mailloux RJ, Jin X, Willmore WG. Redox regulation of mitochondrial function with emphasis on cysteine oxidation reactions. *Redox Biol*. 2014;2:123–139. doi: 10.1016/j.redox.2013.12.011.

42. Riener J, Schwarzländer M, Conrad M, Herrmann JM. Thiol switches in mitochondria: operation and physiological relevance. *Biochim Biophys Acta*. 2015;396:465–482. doi: 10.1015/fbsz-2014-0293.

43. Sekhon B, Sekhon C, Khan M, Patel SJ, Singh I, Singh AK. N-acetyl cysteine protects against injury in a rat model of focal cerebral ischemia. *Brain Res*. 2003;971:1–8.

44. Anderson MF, Nilsson M, Eriksson PS, Sims NR. Glutathione mono-ethyl ester provides neuroprotection in a rat model of stroke. *Neurosci Lett*. 2004;354:163–165.

45. Khan M, Sekhon B, Jatana M, Giri S, Gilg AG, Sekhon C, et al. Administration of N-acetylcysteine after focal cerebral ischemia protects brain and reduces inflammation in a rat model of experimental stroke. *J Neurosci Res*. 2004;76:519–527. doi: 10.1002/jnr.20087.
Critical Role of Flavin and Glutathione in Complex I–Mediated Bioenergetic Failure in Brain Ischemia/Reperfusion Injury
Anja Kahl, Anna Stepanova, Csaba Konrad, Corey Anderson, Giovanni Manfredi, Ping Zhou, Costantino Iadecola and Alexander Galkin

Stroke. published online April 11, 2018;

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://stroke.ahajournals.org/content/early/2018/04/10/STROKEAHA.117.019687
Free via Open Access

Data Supplement (unedited) at:
http://stroke.ahajournals.org/content/suppl/2018/04/11/STROKEAHA.117.019687.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Stroke can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Stroke is online at:
http://stroke.ahajournals.org//subscriptions/
Critical role of flavin and glutathione in complex I-mediated bioenergetic failure in brain ischemia/reperfusion injury

Anja Kahl1*, Anna Stepanova1,2*, Csaba Konrad1, Corey Anderson1, Giovanni Manfredi1, Ping Zhou1, Costantino Iadecola1 and Alexander Galkin1,2

1Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, USA
2School of Biological Sciences, Queen's University Belfast, UK

*These authors contributed equally to this work.
Material & Methods

Experimental animals

Experiments were performed in 7-9 week-old male C57Bl/6J mice (average weight: 23.2±1.1g, Jackson Laboratory) housed in an environmentally controlled room with a 12-hour light/dark cycle and fed a standard chow diet containing 13.2% fat, 24.6% protein and 62.1% carbohydrate (kcal/100 kcal) (#5053, LabDiet) with food and water ad libitum.

Middle Cerebral Artery occlusion model

Transient focal cerebral ischemia was induced in 7-9 week-old male mice using an intraluminal filament model of MCAO. Briefly, mice were anesthetized with 1.5-2.0% isoflurane and rectal temperature was maintained at 37.3±0.3°C using a heating pad (TC-1000, CWE Inc.) during the surgical procedure and in the recovery period until the animals regained full consciousness.

A heat-blunted suture (6-0 suture) was inserted via the right external carotid artery until it obstructed the proximal part of the MCA and the common carotid artery simultaneously ligated for the duration of the ischemic period (35 min). Relative cerebral blood flow (CBF) was measured with transcranial laser Doppler flowmetry (Periflux System 5010, Perimed) in the center of the ischemic territory (coordinates: 2 mm posterior, 5 mm lateral to bregma). After 35 min, the filament was retracted and CBF reestablished. Only animals that exhibited a reduction in CBF of >85% during MCAO and in which CBF recovered by >80% after 10 min of reperfusion were included in the study.

Study timeline and experimental groups

The study was conducted between June 2015 till May 2017 and a total number of 151 animals were used. Overall 7 mice had to be excluded due to insufficient reperfusion (< 80% of relative baseline CBF), 1 mouse died before its 24 hour time-point and 3 mice had to be sacrificed due to bad physical condition before 3 days post-MCAO in the saline-treated control group.

Animals were randomly assigned to sham-operated and MCAO group or GSH ethyl ester treatment and saline treatment group, respectively. A consistent anesthesia time of 70 min was used for each animal in the MCAO and sham-operated group. For the 35 min ischemia only experimental group, the anesthesia time was adjusted to 30 min. This means that after the filament was inserted the CBF was only monitored for 10 min, until the incision site sutured and the animals put back into a preheated recovery cage. A separate corresponding sham served as a control for the ischemia only group.

Motor function testing

To detect a functional impairment three days post-MCAO, we used well-established motor function tests. The hanging wire test was selected to measure differences in grip strength, balance and endurance and the modified Bederson score was used to determine overall
functional outcome after MCAO.

**Measurement of infarct volume**

Infarct volume was measured in Nissl stained coronal brain sections (thickness: 30 μm; interval: 600 μm) throughout the infarcted territory (MCID, Imaging Research, UK) as described previously. Post-ischemic edema was corrected by quantifying the difference in brain volume between the ischemic hemisphere and the contralateral side according to the method described previously.

**Preparation of brain homogenate and mitochondrial isolation**

Following an MCAO period of 35 min only or including a recirculation period of 10, 30 min or 1, 2, 4, 6, 12, 24 h the animals were decapitated and membrane preparation isolated. The brain sample was homogenized in ice-cold isolation buffer (in mmol/L: 210 mannitol, 70 sucrose, 1 EGTA, 5 HEPES, pH 7.4) with 80 strokes of Dounce homogenizer. The homogenate was centrifuged at 1,000 × g for 5 min at 4°C and the supernatant was collected and used for analysis. For isolation of mitochondria, obtained homogenate was centrifugated for 15 min at 20,000 ×g. The resulting membrane pellet was rinsed twice with (in mmol/L) 250 sucrose, 50 Tris-HCl (pH 7.5), 0.2 EDTA medium and subsequently resuspended in the same medium. Frozen aliquots were stored at -80°C until use. Protein content was determined by BCA assay (Sigma) with 0.1% deoxycholate for solubilisation of mitochondrial membranes.

**Mitochondrial respiration measurements**

Mitochondrial respiration in homogenates (0.3±0.06 mg protein) was measured at 37°C in a 2 ml oxygen chamber (Oxygraph-2k, Oroboros Instruments, Innsbruck, Austria). Experimental buffer (in mmol/L: 225 mannitol, 70 sucrose, 5 HEPES, 4 K₂HPO₄, pH 7.4) contained C-I substrates (5 mmol/L glutamate and 2 mmol/L malate) as well as 1 mmol/L MgCl₂ and 0.1 mmol/L EGTA. Measurements were recorded for steady-state basal oxygen consumption and following the addition of 0.2 mmol/L ADP (state 3 respiration), 1 μmol/L oligomycin (state 2 respiration) and 1 mmol/L KCN respectively. The respiratory control ratio (RCR) was calculated as the ratio of ADP-stimulated (state 3) to oligomycin-treated respiration corrected for cyanide-insensitive activity. 100% corresponds to 25.6±1.4 nmol O₂×min⁻¹×mg⁻¹.

**Enzyme activity measurements in mitochondrial membranes**

All activities were measured spectrophotometrically using Molecular Devices SpectraMax plate reader or spectrophotometer Perkin Elmer Lambda 35 in 0.2 or 2 ml of the assay buffer respectively. NADH-dependent enzymatic activities were assayed in SET media (in mmol/L: 50 Tris-Cl pH 7.5, 250 sucrose, and 0.2 EDTA) with 30 μg/mL alamethicin, 1 mmol/L MgCl₂. Succinate:cytochrome c reductase was assayed in KCl media (in mmol/L: 125 KCl, 14 NaCl, 0.2 EGTA, 20 HEPES-Tris, pH 7.2), and succinate:DCIP reductase activity of complex II was assayed in 20 mmol/L HEPES buffer pH 7.8.
Rotenone-sensitive activities of complex I were assayed as a decrease in absorption at 340 nm ($\varepsilon_{340\text{nm}} = 6.22 \text{ L} \cdot \text{mmol}^{-1} \cdot \text{cm}^{-1}$) with 150 µmol/L: NADH in SET media supplemented with 15 µmol/L: cytochrome c for NADH-oxidase or with 1mmol/L KCN and 50 µmol/L Q₁ for NADH:Q₁ reductase activity. 100% corresponds to 206.0±11.2 and 45.4±2.6 nmol NADH×min⁻¹×mg⁻¹ for NADH-oxidase and NADH:Q₁ reductase. Only rotenone sensitive part of activities was taken for the calculations. NADH:hexammineruthenium (HAR) oxidoreductase reductase 6,7 was assayed in the SET medium supplemented with 1 mmol/L cyanide and 1 mmol/L HAR and 0.025% dodecylmaltoside.

Complex II-dependent activities were measured after malonate activation of the sample as described in detail in 8,9. Succinate:DCIP activity was recorded as a decrease in absorption at 600 nm ($\varepsilon_{600\text{nm}} = 21 \text{ L} \cdot \text{mmol}^{-1} \cdot \text{cm}^{-1}$) in HEPES buffer containing 15 mmol/L succinate, 100 µmol/L Q₁, 80 µmol/L DCIP. 100% corresponds to 26.1±1.7 nmol×min⁻¹×mg⁻¹.

Antimycin A sensitive succinate:cytochrome c reductase was measured as an increase in cytochrome c absorption at 550 nm ($\varepsilon_{550\text{nm}} = 21.5 \text{ L} \cdot \text{mmol}^{-1} \cdot \text{cm}^{-1}$) in KCl media, containing 15 mM succinate, 50 µmol/L cytochrome c, and 1 mmol/L KCN. 100% corresponds to 7.5±0.8 nmol×min⁻¹×mg⁻¹.

Complex IV activity was measured as oxidation of 50 µmol/L ferrocytochrome c at 550 nm ($\varepsilon_{550\text{nm}} = 21.0 \text{ L} \cdot \text{mmol}^{-1} \cdot \text{cm}^{-1}$) in 1 mL of SET/2 buffer supplemented with 0.025% dodecylmaltoside. Ferrocytochrome c oxidase activity was fully sensitive to cyanide. 100% corresponds to 658.3±28.7 nmol×min⁻¹×mg⁻¹.

Following protein concentration was used for the measurements of the activities (in µg/ml): NADH oxidase, 25-50; NADH:HAR reductase, 15-25; NADH:Q₁ reductase, 50-100; succinate DCIP reductase, 25-75; succinate:cytochrome c reductase, 100-150.

GSH treatment of the membranes was performed as described earlier with minor modifications.10 To obtain mitochondrial membranes, the homogenates were centrifuged at 20,000 x g for 15 min at 4°C and washed twice with the homogenization buffer. Membranes (10-20 mg/mL of protein) were incubated with 2 mmol/L GSH for 5 minutes in SET media supplemented with 30 µg/mL alamethicin, 1 mmol/L MgCl₂, 60 µmol/L Q₁ and 1 mmol/L KCN. NADH:Q₁ activity was recorded after the addition of 100 µmol/L NADH. NADH:HAR reductase was measured in a similar way.

**Citrate synthase activity assay**

Citrate synthase activity was measured as described earlier,11 with minor modifications. Briefly, frozen-thawed whole tissue homogenates were diluted in 0.01% Triton, and 10 µl of each sample (30 µg protein) were loaded into a well of 96-well plate. Assay media (0.2 mL) contained 20 mmol/L HEPES buffer pH 7.8, 0.1 mmol/L DTNB, 0.4 mmol/L Ac-CoA, 0.4 mmol/L OAA and 30 µg protein. The activity was determined at 412 nm ($\varepsilon_{412\text{nm}} = 14.2 \text{ L} \cdot \text{mmol}^{-1} \cdot \text{cm}^{-1}$) using a plate reader SpectraMax M5 (Molecular Devices). 100% corresponds to 37.8±3.2 nmol×min⁻¹×mg⁻¹ protein⁻¹.

**Determination of membrane bound FMN**
Approximately 100 µg of mitochondria membrane protein was diluted with 20 mmol/L HEPES, pH 7.4, to 1 mg/mL and mixed with an equal volume of 15% TCA for deproteination. After incubation on ice for 10 minutes, protein precipitate was removed by centrifugation at 6,600 x g for 10 min. To neutralize the supernatant, 10 µL of 1 mol/L HEPES pH 7.4, and 20 µL of 5 mol/L KOH were added per 200 µL of the supernatant as previously described with minor modifications.\textsuperscript{12}

Determination of acid-extractable flavin was performed according to Faeder et al.,\textsuperscript{13} with slight modifications. Fluorescence emission was measured at 525 nm, with the excitation at 470 nm (Hitachi F-7000 fluorospectrophotometer) at two different pH (7.6 and 2.3) in 0.1 mol/L phosphate buffer containing 0.1 mmol/L EDTA. Freshly prepared standard solutions of FMN and FAD with known concentration were used for calibration.

**Evaluation of total glutathione content**

After administration of GSH ester, the content of total glutathione (GSH and GSSG) was determined using a Glutathione Assay Kit (703002, Cayman). Briefly, pieces of frozen tissue were homogenized in ten volumes of 50 mmol/L MES buffer pH 6.5, 1 mmol/L EDTA with tissue disruptor (Dremel, Tissue-Tearor). Further steps were performed according to the manufacturer instructions. For the GSSG measurement, samples were incubated with 10 µmol/L 2-vinylpyridine for an hour at room temperature.

**Western Blot**

Immunoblot analyses were performed as previously described,\textsuperscript{9} using total OXPHOS rodent primary antibody cocktail (ab110413, Abcam, diluted 1:1,000 in 3% BSA in TBS+0.01% Triton-X containing five different antibodies against the all OXPHOS complexes. Tim23 staining (1:1,000, BD Transduction Lab) was used to monitor equal gel loading.

**Experimental design and statistical analysis**

GraphPad Prism software (version 7.0, GraphPad Software) was used for all statistical analysis. Data are expressed as mean±SEM. Intergroup differences between two groups were analyzed by unpaired Student’s t test or non-parametric Mann-Whitney U test, as appropriate. If more than two groups were analyzed and compared to sham, one-way ANOVA with Dunnett’s multiple comparisons test or Kruskal Wallis test with Dunn’s multiple comparisons test was used. Ordinary one-way ANOVA with Tukey’s multiple comparisons test was performed if multiple groups were compared to each other. As for the in vitro experiment with GSH treatment of the mitochondrial membranes, differences were analyzed by paired Student’s t test. Differences were considered statistically significant for *p*<0.05. For the in vivo GSH study the number of experimental animals required to detect a standardized effect size > 0.25 was calculated by a priori power analysis with the following assumptions: power = 0.8 and α = 0.05, SD 20% of the mean (GPower 3.1 software).
Figure I. Protein levels of individual respiratory chain complexes and respiratory control did not change after focal cerebral ischemia. (A) No changes in respiratory control ratio (RCR), a parameter reflecting the integrity of the mitochondrial inner membrane, did not change at any time point during the first 24 h of reperfusion (p>0.05; n=4-7 mice per group) compared to sham-operated controls (n=19). (B,C) Representative immunoblot analysis including abundance quantification of mitochondrial respiratory chain complex subunits from whole tissue homogenates after 35 min ischemia and the first 24 h after reperfusion. The band intensities were normalized to the mitochondrial membrane protein Tim23, p>0.05, n=3.
Figure II. GSH ester treated mice show improved overall outcome 72 h after focal cerebral ischemia. (A) Body weight loss analysis of GSH ester and control mice 72 h after MCAO (n= 8-9 mice per group, p=0.0037, unpaired t test). (B) GSH treated mice show an improved modified Bederson score; n=8-9 mice per group 72 h after MCAO.
Supplemental References:

1. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research. *PLoS Biol.* 2010;8:e1000412

2. Jackman K, Kunz A, Iadecola C. Modeling focal cerebral ischemia in vivo. *Methods Mol Biol.* 2011;793:195-209

3. Abe T, Shimamura M, Jackman K, Kurinami H, Anrather J, Zhou P, et al. Key role of cd36 in toll-like receptor 2 signaling in cerebral ischemia. *Stroke.* 2010;41:898-904

4. Balkaya M, Krober JM, Rex A, Endres M. Assessing post-stroke behavior in mouse models of focal ischemia. *J Cereb Blood Flow Metab.* 2013;33:330-338

5. Lin TN, He YY, Wu G, Khan M, Hsu CY. Effect of brain edema on infarct volume in a focal cerebral ischemia model in rats. *Stroke.* 1993;24:117-121

6. Sled VD, Vinogradov AD. Kinetics of the mitochondrial NADH-ubiquinone oxidoreductase interaction with hexammineruthenium (iii). *Biochim. Biophys. Acta.* 1993;1141:262-268

7. Birrell JA, Yakovlev G, Hirst J. Reactions of the flavin mononucleotide in complex I: A combined mechanism describes nadh oxidation coupled to the reduction of APAD+, ferricyanide, or molecular oxygen. *Biochemistry.* 2009;48:12005-12013

8. Ackrell BA, Kearney EB, Singer TP. Mammalian succinate dehydrogenase. *Methods Enzymol.* 1978;53:466-483

9. Stepanova A, Shurubor Y, Valsecchi F, Manfredi G, Galkin A. Differential susceptibility of mitochondrial complex ii to inhibition by oxaloacetate in brain and heart. *Biochim. Biophys. Acta.* 2016;1857:1561-1568

10. Galkin A, Moncada S. S-nitrosation of mitochondrial complex i depends on its structural conformation. *J. Biol. Chem.* 2007;282:37448-37453

11. Srere PA. Citrate synthase. *Methods Enzymol.* 1969;13:3-11

12. Merola AJ, Coleman R, Hansen R. Flavin mononucleotide: The acid-extractable flavin of the DPNH-coenzyme q reductase of the respiratory chain. *Biochim. Biophys. Acta.* 1963;73:638-640

13. Faeder EJ, Siegel LM. A rapid micromethod for determination of FMN and FAD in mixtures. *Anal Biochem.* 1973;53:332-336